User:Mr. Ibrahem/Upadacitinib

Upadacitinib, sold under the brand name Rinvoq, is a medication used to treat moderate to severe rheumatoid arthritis (RA) where methotrexate was not sufficiently effective. While it may be used together with conventional RA medication, use with immunosuppressive agent is not recommended. It is taken by mouth.

Common side effects include upper respiratory tract infections (such as the common cold), nausea, cough, and fever. Other side effects may include serious infections, blood clots, and cancer. Use during pregnancy may harm the baby. Use in those with active tuberculosis is not recommended. Upadacitinib works by blocking the action of enzymes called Janus kinases, which results in decreased inflammation.

Upadacitinib was approved for medical use in Europe and the United States in 2019. Per year, in Canada it costs about 18,000 CAD as of 2019, in the United States it costs about 67,000 USD, while in the United Kingdom this amount costs the NHS about £10,500 as of 2021.